Activation and modulation of eosinophils by chemokines;Aktivierung und modulation eosinophiler granulozyten durch chemokine: Ihre bedeutung fur die allergische entzundung

Allergologie

Volumn 23, Issue 2, 2000, Pages 59-72

  Elsner, J ^a   Kapp, A ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NONE

Author keywords

Allergy; Chemokine receptor; Chemokines; Eosinophil; Therapy

Indexed keywords

CHEMOKINE; COMPLEMENT COMPONENT C5A; EOSINOPHIL CATIONIC PROTEIN; EOTAXIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 5; MAJOR BASIC PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 4; RANTES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ALLERGIC ASTHMA; ANTIGEN PRESENTING CELL; ARTICLE; ATOPIC DERMATITIS; EFFECTOR CELL; EOSINOPHIL; HUMAN; IMMUNOMODULATION; INFLAMMATION; LEUKOCYTE ACTIVATION; MEDIATOR RELEASE; RHINOCONJUNCTIVITIS; TH2 CELL; TISSUE INJURY;

EID: 0033997071     PISSN: 03445062     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (136)

1. Bachert C., M. Wagenmann, G. Holtappels: Cytokines and adhesion molecules in allergic rhinitis. Am. J. Rhinol. 12, 3-8 (1998).
2. Bachert C., M. Wagenmann, C. Rudack, K. Hopken, M. Hillebrandt, D. Wang, P. van Cauwenberge: The role of cytokines in infectious sinusitis and nasal polyposis. Allergy 53, 2-13 (1998).
3. Baggiolini M.: Chemokines and leukocyte traffic. Nature 392, 565-568 (1998).
4. Baggiolini M., B. Moser: Blocking chemokine receptors. J. Exp. Med. 186, 1189-1191 (1997).
5. Bartels J., C. Schluter, E. Richter, N. Noso, R. Kulke, E. Christophers, J.M. Schroder: Human dermal fibroblasts express eotaxin: molecular cloning, mRNA expression, and identification of eotaxin sequence variants. Biochem. Biophys. Res. Commun. 225, 1045-1051 (1996).
6. Bazan J.F., K.B. Bacon, G. Hardiman, W. Wang, K. Soo, D. Rossi, D.R. Greaves, A. Zlotnik, T.J. Schall: A new class of membrane-bound chemokine with a CX3C motif. Nature 385, 640-644 (1997).
7. Beck L.A., C. Stellato, L.D. Beall, T.J. Schall, D. Leopold, C.A. Bickel, F. Baroody, B.S. Bochner, R.P. Schleimer: Detection of the chemokine RANTES and endothelial adhesion molecules in nasal polyps. J. Allergy Clin. Immunol. 98, 766-780 (1996).
8. Ben-Baruch A., L. Xu, P.R. Young, K. Bengali, J.J. Oppenheim, J.M. Wang: Monocyte chemotactic protein-3 (MCP-3) interacts with multiple leukocyte receptors - C-C CKR1, a receptor for macrophage inflammatory protein-1a/RANTES, is also a functional receptor for MCP-3. J. Biol. Chem. 270, 22123-22128 (1995).
9. Bentley A.M., Q. Hamid, D.S. Robinson, E. Schotman, Q. Meng, B. Assoufi, A.B. Kay, S.R. Durham: Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am. J. Respir. Crit. Care Med. 153, 551-556 (1996).
10. Bonini S., L. Magrini, G. Rotiroti, A. Lambiase, M. Tomassini, C. Rumi: The eosinophil and the eye. Allergy 52, 44-47 (1997).
11. Butterworth A.E., K.J.I. Thorne: Eosinophils and parasitic diseases. In: Smith H., R.M. Cook: Immunopharmacology of Eosinophils. Academic Press, London 1993, 119-150.
12. Collins P.D., V.B. Weg, L.H. Faccioli, M.L Watson, R. Moqbel, T.J. Williams: Eosinophil accumulation induced by human interleukin-8 in the guinea-pig in vivo. Immunology 79, 312-318 (1993).
13. Cotton S.A., A.L. Herrick, M.I. Jayson, A.J. Freemont: TGF beta - a role in systemic sclerosis? J. Pathol. 184, 4-6 (1988).
14. Coyle A.J., S. Ackermann, R. Burch, D. Proud, C.G. Irvin: Human eosinophil granule major basic protein and synthetic polycations induce airway hyperresponsiveness in vivo dependent on bradykinin generation. J. Clin. Invest. 95, 1735-1740 (1995).
15. Coyle A.J., F. Perretti, S. Manzini, C.G. Irvin: Cationic protein induced sensory nerve activation - Role of substance P in airway hyperresponsiveness and plasma protein extravasation. J. Clin. Invest. 94, 2301-2306 (1994).
16. Daugherty B.L., S.J. Siciliano, J.A. DeMartino, L. Malkowitz, A. Sirotina, M.S. Springer: Cloning, expression, and characterization of the human eosinophil eotaxin receptor. J. Exp. Med. 183, 2349-2354 (1996).
17. Desreumaux P., A. Janin, S. Dubucquoi, M.C. Copin, G. Torpier, A. Capron, M. Capron, L. Prin: Synthesis of interleukin-5 by activated eosinophils in patients with eosinophilic heart diseases. Blood 82, 1553-1560 (1993).
18. Dhami D., J.K. Shutte: Mechanisms of epithelial damage: are there parallels between bullous skin diseases and asthma? Clin. Exp. Allergy 24, 1005 (1994).
19. Druilhe A., Z. Cai, S. Haile, S. Chouaib, M. Pretolani: Fas-mediated apoptosis in cultured human eosinophils. Blood 87, 2822-2830 (1996).
20. Ehrlich P.: Beiträge zur Kenntnis der granulierenden Bindegewebszellen und der eosinophilen Leukozyten. Arch. Anat. Physiol. 166-177 (1879).
21. Elsner J.: Eosinophile Zellulitis (Wells-Syndrom). In: Weiss J., A. Kapp: Systemische Kortikoide in der dermatologischen Therapie. Aktuelles Wissen Höchst, Frankfurt 1997, 20-23.
22. Elsner J., S. Dichmann, G.J. Dobos, A. Kapp: Actin polymerization in human eosinophils, unlike human neutrophils, depends on intracellular calcium mobilization. J. Cell Physiol. 167, 548-555 (1996).
23. Elsner J., S. Dichmann, A. Kapp: Activation of the respiratory burst in human eosinophils by chemotaxins requires intracellular calcium fluxes. J. Invest. Dermatol. 105, 231-236 (1995).
24. Elsner J., R. Hochstetter, D. Kimmig, A. Kapp: Human eotaxin represents a potent activator of the respiratory burst of human eosinophils. Eur. J. Immunol. 26, 1919-1925 (1996).
25. Elsner J., R. Hochstetler, K. Spiekermann, A. Kapp: Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 88, 4684-4693 (1996).
26. Elsner J., M. Oppermann, W. Czech, G. Dobos, E. Schöpf, J. Norgauer, A. Kapp: C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur. J. Immunol. 24, 518-522 (1994).
27. Elsner J., M. Oppermann, W. Czech, A. Kapp: C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin-sensitive G-proteins. Blood 83, 3324-3331 (1994).
28. Elsner J., M. Oppermann, A. Kapp: Detection of C5a receptors on human eosinophils and inhibition of eosinophil effector functions by anti-C5a receptor (CD88) antibodies. Eur. J. Immunol. 26, 1560-1564 (1996).
29. Elsner J., H. Petering, R. Hochstetter, D. Kimmig, T.N. Wells, A. Kapp, A.E. Proudfoot: The CC chemokine antagonist Met-RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3. Eur. J. Immunol. 27, 2892-2898 (1997).
30. Elsner J., H. Petering, C. Kluthe, D. Kimmig, R. Smolarski, P. Ponath, A. Kapp: Eotaxin-2 activates chemotaxis-related events and release of reactive oxygen species via pertussis toxin-sensitive G proteins in human eosinophils. Eur. J. Immunol. 28, 2152-2158 (1998).
31. Erger R.A., T.B. Casale: Interleukin-8 is a potent mediator of eosinophil chemotaxis through endothelium and epithelium. Am. J. Physiol. 268, L117-122 (1995).
32. Forssmann U., M. Uguccioni, P. Loetscher, C.A. Dahinaen, H. Langen, M. Thelen, M. Baggiolini: Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. J. Exp. Med. 185, 2171-2176 (1997).
33. Gao J.L., D.B. Kuhns, H.L. Tiffany, D. McDermott. X. Li, U. Francke, P.H. Murphy: Structure and functional expression of the human macrophage inflammatory 1a/RANTES receptor. J. Exp. Med. 177, 1421-1427 (1993).
34. Garzino-Demo A., A.L. DeVico, R.C. Gallo: Chemokine receptors and chemokines in HIV infection. J. Clin. Immunol. 18, 243-255 (1998).
35. Gleich G.J., C.R. Adolphoson, K.M. Leiferman: The biology of the eosinophilic leukocyte. Annu. Rev. Med. 44, 85-101 (1993).
36. Goetzl E.J., S.I. Wasserman, F. Austen: Eosinophil polymorphonuclear leukocyte function in immediate hypersensitivity. Arch. Pathol. 99, 1-4 (1975).
37. 2-terminal residues. J. Exp. Med. 181, 631-640 (1995).
38. Gong J.H., M. Uguccioni, B. Dewald, M. Baggiolini, I. Clark Lewis: RANTES and MCP-3 antagonists bind multiple chemokine receptors. J. Biol. Chem. 271, 10521-10527 (1996).
39. Grewe M., C.A.F.M. Bruijnzeel-Koomen, E. Schöpf, T. Thepen, A.G. Langeveld-Wildschut, T. Ruzicka, J. Krutmann: A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol. Today 19, 359-361 (1998).
40. Grewe M., W. Czech, A. Morita, T. Werfel, M. Klammer, A. Kapp, T. Ruzicka, E. Schopf. J. Krutmann: Human eosinophils produce biologically active IL-12: implications for control of T cell responses. J. Immunol. 161, 415-420 (1998).
41. Grewe M., S. Walter, K. Gyufko, W. Czech, E. Schöpf, J. Krutmann: Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients. J. Invest. Dermatol. 105, 407-410 (1995).
42. Hale G., M.Q. Xia, H.P. Tighe, M.J.S. Dyer, H. Waldmann: The CAMPATH-1 antigen (CDw52). Tissue Antigens 35, 118-127 (1990).
43. Haskell M.D., J.N. Moy, G.J. Gleich, L.L. Thomas: Analysis of signaling events associated with activation of neutrophil superoxide anion production by eoshophil granule major basic protein. Blood 86, 4627-4637 (1995).
44. Heath H., S. Qin, P. Rao, L. Wu, G. LaRosa, N. Kassam, P.D. Ponath, C.R. Mackay: Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J. Clin. Invest. 99, 178-184 (1997).
45. Hebestreit H., B. Dibbert, I. Balatti, D. Braun, A. Schapowal, K. Blaser, H.U. Simon: Disruption of fas receptor signaling by nitric oxide in eosinophils. J. Exp. Med. 187, 415-425 (1998).
46. Hogg J.C.: The pathology of asthma. APMIS 105, 735-745 (1997).
47. Isaacs J.D., V.K. Manna, N. Rapson, K.J. Bulpitt, B.L. Hazleman, E.L. Matteson, E.W. St. Clair, T.J. Schnitzer, J.M. Johnston: CAMPATH-1H in rheumatoid arthritis - an intravenous dose-ranging study. Br. J. Rheumatol. 35, 231-240 (1996).
48. Kapp A.: Atopic dermatitis - the skin manifestation of atopy. Clin. Exp. Allergy 25, 210-219 (1995).
49. Kapp A., G. Zeck Kapp, W. Czech, E. Schöpf: The chemokine RANTES is more than a chemoattractant: Characterization of its effect on human eosinophil oxidative metabolism and morphology in comparison with IL-5 and GM-CSF. J. Invest. Dermatol. 102, 906-914 (1994).
50. Karpus W.J., R.M. Ransohoff: Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis. J. Immunol. 161, 2667-2671 (1998).
51. Kiehl P., A. Kapp: Tissue eosinophilia and local deposition of eosinophil-specific granule proteins. Regulation and significance for inflammatory response in atopic dermatitis and other inflammatory dermatoses. Hautarzt 49, 176-183 (1998).
52. Kita H., R.I. Abu-Ghazaleh, S. Sur, G.J. Gleich: Eosinophil major basic protein induces degranulation and IL-8 production by human eosinophils. J. Immunol. 154, 4749-4758 (1995).
53. Kitaura M., T. Nakajima, T. Imai, S. Harada, C. Combadiere, H.L. Tiffany, P.M. Murphy, O. Yoshie: Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3. J. Biol. Chem. 271, 7725-7730 (1996).
54. Krause J.R., D.R. Boggs: Search for eosinopenia in hospitalized patients with normal blood leukocyte concentration. Am. J. Hematol. 24, 55-63 (1987).
55. Kuroda K., H. Shinkai: Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch. Dermatol. Res. 289, 567-572 (1997).
56. Lacy P., F. Levi-Schaffer, S. Mahmudi-Azer, B. Bablitz, S.C. Hagen, J. Velazquez, A.B. Kay, R. Moqbel: Intracellular localization of interleukin-6 in eosinophils from atopic asthmatics and effects of interferon gamma. Blood 91, 2508-2516 (1998).
57. Lamkhioued B., D. Aldebert, A.S. Gounni, E. Delaporte, M. Goldman, A. Capron, M. Capron: Synthesis of cytokines by eosinophils and their regulation. Int. Arch. Allergy Immunol. 107, 122-123 (1995).
58. Leiferman K.M.: Eosinophils in atopic dermatitis. J. Allergy Clin. Immunol. 94, 1310-1317 (1994).
59. Leiferman K.M., S.J. Ackermann, H.A. Sampson, H.S. Haugen, P.Y. Venencie, G.J. Gleich: Dermal deposition of eosinophili-graule major basic protein in atopic dermatitis. Comparison with onchocerciasis. N. Engl. J. Med. 313, 282-285 (1985).
60. Levi Schaffer F., J. Barkans, T.M. Newman, S. Ying, M. Wakelin, R. Hohenstein, V. Barak, P. Lacy, A.B. Kay, R. Mogbel: Identification of interleukin-2 in human peripheral blood eosinophils. Immunology 87, 155-161 (1996).
61. Levi Schaffer F., P. Lacy, N.J. Severs, T.M. Newman, J. North, B. Gomperts, A.B. Kay, R. Moqbel: Association of granulocyte-macrophage colony-stimulating factor with the crystalloid granules of human eosinophils. Blood 85, 2579-2586 (1995).
62. Levi-Schaffer F., V.B. Weg: Mast cells, eosinophils and fibrosis. Clin. Exp. Allergy. 27 (Suppl. 1), 64-70 (1997).
63. Lim K.G., H.C. Wan, P.T. Bozza, M.B. Resnick, D.T.W. Wong, W.W. Cruikshank, H. Kornfeld, D.M. Center, P.F. Weller: Human eosinophils elaborate the lymphocyte chemoattractants - IL-16 (lymphocyte chemoattractant factor) and RANTES. J. Immunol. 156, 2566-2570 (1996).
64. Liu R., W.A. Paxton, S. Choe, D. Ceradini, S.R. Martin, R. Horuk, M.E. MacDonald, H. Stuhlmann, R.A. Koup, N.R. Landau: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply exposed individuals to HIV-1 infection. Cell 86, 367-377 (1996).
65. Lukacs N.W., S.L. Kunkel: Chemokines and their role in disease. Int. J. Clin. Lab. Res. 28, 91-95 (1998).
66. Luster A.D.: Chemokines - chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338, 436-445 (1998).
67. Luster A.D., M.E. Rothenberg: Role of the monocyte chemoattractant protein and eotaxin subfamily of chemokines in allergic inflammation. J. Leukoc. Biol. 62, 620-633 (1997).
68. Luttmann W., P. Franz, H. Matthys, J.C. Virchow Jr.: Effects of TGF-beta on eosinophil chemotaxis. Scand. J. Immunol. 47, 127-130 (1998).
69. Luttmann W., B. Knoechel, M. Foerster, H. Matthys, J.C. Virchow Jr., C. Kroegel: Activation of human eosinophils by IL-13. Induction of CD69 surface antigen, its relationship to messenger RNA exression, and promotion of cellular viability. J. Immunol. 157, 1678-1683 (1996).
70. Luttmann W., A. Opfer, E. Dauer, M. Foerster, H. Matthys, H. Eibel, K. Schulze-Osthoff, C. Kroegel, J.C. Virchow: Differential regulation of CD95 (Fas/APO-1) expression in human blood eosinophils. Eur. J. Immunol. 28, 2057-2065 (1998).
71. Mack M., B. Luckow, P.J. Nelson, J. Cihak, G. Simmons, P.R. Clapham, N. Signoret, M. Marsh, M. Stangassinger, F. Borlat, T.N.C. Wells, D. Schlondorff, A.E.I. Proudfoot: Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: A novel inhibitory mechanism of HIV infectivity. J. Exp. Med. 187, 1215-1224 (1998).
72. Mackay C.R.: Chemokine receptors and T cell chemotaxis. J. Exp. Med. 184, 799-802 (1996).
73. Maggi E.: The TH1/TH2 paradigm in allergy. Immunotechnology 3, 233-244 (1998).
74. Matsumoto K., R.P. Schleimer. H. Saito, Y. Iikura, B.S. Bochner: Induction of apoptosis in human eosinophils by anti-fas antibody treatment in vitro. Blood 86, 1437-1443 (1995).
75. Matteson E.L. D.E. Yocum, E.W. St. Clair, A.A. Achkar, M.S. Thakor, M.R. Jacobs, A.E. Hays, C.K. Heitman, J.M. Johnston: Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthritis Rheum. 38, 1187-1193 (1995).
76. Meagher L.C., J.M. Cousin, J.R. Seckl, C. Haslett: Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J. Immunol. 156, 4422-4428 (1996).
77. Moser B., M. Loetscher, L. Piali, P. Loetscher: Lymphocyte responses to chemokines. Int. Rev. Immunol. 16, 323-344 (1998).
78. Nakajima T., H. Yamada, M. Iikura, M. Miyamasu, S. Izumi, H. Shida, K. Ohta, T. Imai, O. Yoshie, M. Mochizuki, J.M. Schroder, Y. Morita, K. Yamamoto, K. Hirai: Intracellular localization and release of eotaxin from normal eosinophils. FEBS Lett. 434, 226-230 (1998).
79. 2+ influx in neutrophils via a pertussis-toxin-sensitive G protein. Eur. J. Biochem. 217, 289-294 (1993).
80. Oravecz T., M. Pall, G. Roderiquez, M.D. Gorrell, M. Ditto, N.Y. Nguyen, R. Boykins, E. Unsworth, M.A. Norcross: Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV- (CD26) mediated cleavage. J. Exp. Med. 186, 1865-1872 (1997).
81. Osterborg A., A.S. Fassas, A. Anagnostopoulos, M.J. Dyer, D. Catovsky, H. Mellsredt: Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br. J. Haematol. 93, 151-153 (1996).
82. Patella V., G. de Crescenzo, I. Marino, A. Genovese, M. Adt, G.J. Gleich, G. Marone: Eosinophil granule proteins activate human heart mast cells. J. Immunol. 157, 1219-1225 (1996).
83. Pease J.E., J. Wang, P.D. Ponath, P.M. Murphy: The N-terminal extracellular segments of the chemokine receptors CCR1 and CCR3 are determinants for MIP-1alpha and eotaxin binding, respectively, hut a second domain is essential for efficient receptor activation. J. Biol. Chem. 273, 19972-19976 (1998).
84. Petering H., O. Götze, D. Kimmig, R. Smolarski, A. Kapp. J. Elsner: The biologic role of interleukin-8: Functional analysis and expression of CXCR1 and CXCR2 on human eosinophils. Blood 93, 694-702 (1999).
85. Petering H., R. Hochstetter; D. Kimmig, R. Smolarski, A. Kapp, J. Elsner: Detection of MCP-4 in dermal fibroblasts and its activation of the respiratory burst in human eosinophils. J. Immunol. 160, 555-558 (1998).
86. Petering H., J. Köhl, A. Weyergraf, D. Kimmig, R. Smolarski, A. Kapp, J. Elsner: Short synthetic C3a analog peptides: activation profile of human eosinophils in comparison to the native complement component C3a. Submitted (1999).
87. Plater-Zyberk C., A.J. Hoogewerf, A.E. Proudfoot, C.A. Power, T.N. Wells: Effect of a CC chemokine receptor antagonist on collagen-induced arthritis in DBA/1 mice. Immunol. Lett. 57, 117-120 (1997).
88. Ponath P.D., S. Qin, T.W. Post, J. Wang, L. Wu, N.P. Gerard, W. Newman, C. Gerard, C.R. Mackay: Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J. Exp. Med. 183, 2437-2448 (1996).
89. Proost P., I. De Meester, D. Schols, S. Struyf, A.M. Lambeir, A. Wuyts, G. Opdenakker, E. De Clercq, S. Scharpe, J. Van Damme: Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J. Biol. Chem. 273, 7222-7227 (1998).
90. Proost P., S. Struyf, M. Couvreur, J.P. Lenaerts, R. Conings, P. Menten, P. Verhaert, A. Wuyts, J. Van Damme: Posttranslational modifications affect the activity of the human monocyte chemotactic proteins MCP-1 and MCP-2: identification of MCP-2(6-75) as a natural chemokine inhibitor. J. Immunol. 160, 4034-4041 (1998).
91. Proudfoot A.E., C.A. Power, A.J. Hoogewerf, M.O. Montjovent, F. Borlat, R.E. Offord, T.N. Wells: Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J. Biol. Chem. 271, 2599-2603 (1996).
92. Quillent C., E. Oberlin, J. Braun, D. Rousset, G. Gonzalez-Canali, P. Metais, L. Montagnier, J.L. Virelizier, F. Arenzana-Seisdedos, A. Beretta: HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene (see comments). Lancet 351, 14-18 (1998).
93. Rozell M.D., R.A. Erger, T.B. Casale: Isolation technique alters eosinophil migration response to IL-8. J. Immunol. Methods 197, 97-107 (1996).
94. Sallusto F., A. Lanzavecchia, C.R. Mackay: Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol. Today 19, 568-574 (1998).
95. Sallusto F., D. Lenig, C.R. Mackay, A. Lanzavecchia: Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med. 187, 875-883 (1998).
96. Sallusto F., C.R. Mackay, A. Lanzavecchia: Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 277, 2005-2007 (1997).
97. Schweizer R.C., B.A. Welmers, J.A. Raaijmakers, P. Zanen, J.W. Lammers, L. Koenderman: RANTES- and interleukin-8-induced responses in normal human eosinophils: effects of priming with interlcukin-5. Blood 83, 3697-3704 (1994).
98. Schwenk U., J.M. Schröder: 5-oxo-eicosanoids are potent eosinophil chemotactic factors: Functional characterization and structural requirements. J. Biol. Chem. 270, 15029-15036 (1995).
99. Simmons G., P.R. Clapham, L. Picard, R.E. Offord, MM. Rosenkilde, T.W. Schwartz, R. Buser, T.N.C. Wells, A.E. Proudfoot: Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276, 276-279 (1997).
100. Simon H.U., K. Blaser: Inhibition of programmed eosinophil death: A key pathogenetic event for eosinophilia? Immunol. Today 16, 53-55 (1995).
101. Simon H.U., S. Yousefi, B. Dibbert, F. Levi-Schaffer, K. Blaser: Anti-apoptotic signals of granulocytemacrophage colony-stimulating factor are transduced via Jak2 tyrosine kinase in eosinophils. Eur. J. Immunol. 27, 3536-3539 (1997).
102. Stern M., L. Meagher, J. Savill, C. Haslett: Apoptosis in human eosinophils. Programmed cell death in the eosinophil leads to phagocytosis by macrophages and is modulated by IL-5. J. Immunol. 148, 3543-3549 (1992).
103. Struyf S., I. De Meester, S. Scharpe, J.P. Lenaerts, P. Menten, J.M. Wang, P. Proost, J. Van Damme: Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor. Eur. J. Immunol. 28, 1262-1271 (1998).
104. Sur S., H. Kita, G.J. Gleich, T.C. Chenier, L.W. Hunt: Eosinophil recruitment is associated with IL-5, but not with RANTES, twenty-four hours after allergen challenge. J. Allergy Clin. Immunol. 97, 1272-1278 (1995).
105. Teixeira M.M., T.N. Wells, N.W. Lukacs, A.E. Proudfoot, S.L. Kunkel, J.T. Williams, P.G. Hellewell: Chemokine-induced eosinophil recruitment. Evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin. J. Clin. Invest. 100, 1657-1666 (1997).
106. Teran L.M., N. Noso, M. Carroll, D.E. Davies, S. Holgate, J.M. Schröder: Eosinophil recruitment following allergen challenge is associated with the release of the chemokine RANTES into asthmatic airways. J. Immunol. 157, 1806-1812 (1996).
107. Terkeltaub R., W.A. Boisvert, L.K. Curtiss: Chemokines and atherosclerosis. Curr. Opin. Lipidol. 9, 397-405 (1998).
108. Tiffany H.L., G. Alkhatib, C. Combadiere, E.A. Berger, P.M. Murphy: CC chemokine receptors 1 and 3 are differentially regulated by IL-5 during maturation of eosinophilic HL-60 cells. J. Immunol. 160, 1385-1392 (1998).
109. Tsuyuki S., C. Bertrand, F. Erard, A. Trifilieff, J. Tsuyuki, M. Wesp, G.P. Anderson, A.J. Coyle: Activation of the Fas receptor on lung eosinophils leads to apoptosis and the resolution of eosinophilic inflammation of the airways. J. Clin. Invest. 96, 2924-2931 (1995).
110. Uguccioni M., C.R. Mackay, B. Ochensberger, P. Loetscher, S. Rhis, G.J. LaRosa, P. Rao, P.D. Ponath, M. Baggiolini, C.A. Dahinden: High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, mcp-4, and other chemokines. J. Clin. Invest. 100, 1137-1143 (1997).
111. Varga J., V.M. Kahari: Eosinophilia-myalgia syndrome, eosinophilic fasciitis, and related fibrosing disorders. Curr. Opin. Rheumatol. 9, 562-570 (1997).
112. Walsh G.M., M.L Williamson, F.A. Symon, G.B. Willars, A.J. Wardlaw: Ligation of CD69 induces apoptosis and cell death in human eosinophils cultured with granulocyte-macrophage colony-stimulating factor. Blood 87, 2815-2821 (1996).
113. Wang J.M., X. Deng, W. Gong, S. Su: Chemokines and their role in tumor growth and metastasis. J. Immunol. Meth. 220, 1-17 (1998).
114. Wang J.M., S. Su, W. Gong, J.J. Oppenheim: Chemokines, receptors, and their role in cardiovascular pathology. Int. J. Clin. Lab. Res. 28, 83-90 (1998).
115. Ward S.G., J. Westwick: Chemokines, understanding their role in T-lymphocyte biology. Biochem. J. 333, 457-470 (1998).
116. 2-terminal residue converts monocyte chemotactic protein 1 from an activator of basophil mediator release to an eosmophil chemoattractant. J. Exp. Med. 183, 681-685 (1996).
117. Wedi B., U. Raap, H. Lewrick, A. Kapp: Delayed eosinophil programmed cell death in vitro: a common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis. J. Allergy Clin. Immunol. 100, 536-543 (1997).
118. Weiler J.M., R.E. Edens, G.J. Gleich: Eosinophil granule cationic proteins regulate complement. I. Activity on the alternative pathway. J. Immunol. 149, 643-648 (1992).
119. Weller P.F., E.J. Goetzl: The regulatory and effector roles of eosinophils. Adv. Immunol. 27, 339-371 (1979).
120. Wells T.N., C.A. Power, A.E. Proudfoot: Definition, function and pathophysiological significance of chemokine receptors. Trends Pharmacol. Sci. 19, 376-380 (1998).
121. Wells T.N.C., C.A. Power, M. Lusti-Narasimhan, A.J. Hoogewerf, R.M. Cooke, C. Chung, M.C. Peitsch, A.E.I. Proudfoot: Selectivity and antagonism of chemokine receptors. J. Leukoc. Biol. 59, 53-60 (1996).
122. White J.R., C. Imburgia, E. Dul, E. Appelbaum, K. O'Donnell, D.J. O'Shannessy, M. Brawner, J. Fornwald, J. Adamou, N.A. Elshourbagy, K. Kaiser, J.J. Foley, D.B. Schmidt, K. Johanson, C. Macphee, K. Moores, D. McNulty, G.F. Scott, R.P. Schleimer, H.M. Sarau: Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophils. J. Leukoc. Biol. 62, 667-675 (1997).
123. Winkel P., B.E. Statland, A.M. Saunders, H. Osborn, H. Kupperman: Within-day physiologic variation of leukocyte types in healthy subjects as assayed by two automated leukocyte differential analyzers. Am. J. Clin. Pathol. 75, 693-700 (1981).
124. Woolley K.L., P.G. Gibson, K. Carty, A.J. Wilson, S.H. Twadell, M.J. Woolley: Eosinophil apoptosis and the resolution of airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 154, 237-243 (1996).
125. Yamaguchi Y., T. Suda, S. Ohta, K. Tominaga, Y. Miura, T. Kasahara: Analysis of the survival of mature human eosinophils: Interleukin 5 prevents apoptosis in mature human eosinophils. Blood 78, 2542-2547 (1991).
126. Ying S., Q. Meng, L. Taborda Barata, C.J. Corrigan, J. Barkans, B. Assoufi, R. Moqbel, S.R. Durham, A.B. Kay: Human eosinophils express messenger RNA encoding RANTES and store and release biologically active RANTES protein. Eur. J. Immunol. 26, 70-76 (1996).
127. Ying S., D.S. Robinson, Q. Meng, J. Rottman, R. Kennedy, D.J. Ringler, C.R. Mackay, B.L. Daugherty, M.S. Springer, S.R. Durham, T.J. Williams, A.B. Kay: Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur. J. Immunol. 27, 3507-3516 (1997).
128. Yousefi S., D.R. Green, K. Blaser, H.U. Simon: Protein-tyrosine phosphorylation regulates apoptosis in human eosinophils and neutrophils. Proc. Natl. Acad. Sci. USA 91, 10868-10872 (1994).
129. Yousefi S., S. Hemmann, M. Weber, C. Hölzer, K. Hartung, K. Blaser, H.U. Simon: IL-8 is expressed by human peripheral blood eosinophils - Evidence for increased secretion in asthma. J. Immunol. 154, 5481-5490 (1995).
130. Yousefi S., D.C. Hoessli, K. Blaser, G.B. Mills, H.U. Simon: Requirement of lyn and syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils. J. Exp. Med. 183, 1407-1414 (1996).
131. Zagury D., A. Lachgar, V. Chams, L.S. Fall, J. Bernard, J.F. Zagury, B. Bizzini, A. Gringeri, E. Santagostino, J. Rappaport, M. Feldman, S.J. O'Brien, A. Burny, R.C. Gallo: C-C chemokines, pivotal in protection against HIV type 1 infection. Proc. Natl. Acad. Sci. USA 95, 3857-3861 (1998).
132. Zeck-Kapp G., A. Kapp: Subcellular mechanisms of eosinophil degranulation: The role of RANTES, interleukin-5 and tumor necrosis factor-alpha. Int. Arch. Allergy Immunol. 107, 345 (1995).
133. Zeck-Kapp G., C. Kroegel, U.N. Riede, A. Kapp: Mechanisms of human eosinophil activation by complement protein C5a and platelet-activating factor: Similar functional responses are accompanied by different morphologic alterations. Allergy 50, 34-47 (1995).
134. Zheutlin L.M., S.J. Ackerman, G.J. Gleich, L.L. Thomas: Stimulation of basophil and rat mast cell histamine release by eosinophil granule-derived cationic proteins. J. Immunol. 133, 2180-2185 (1984).
135. Zwirner J., O. Gotze, A. Moser, A. Sieber, G. Begemann, A. Kapp, J. Elsner, T. Werfel: Blood- and skin-derived monocytes/macrophages respond to C3a but not to C3a (desArg) with a transient release of calcium via a pertussis toxin-sensitive signal transduction pathway. Eur. J. Immunol. 27, 2317-2322 (1997).
136. Zwirner J., O. Gotze, A. Sieber, A. Kapp, G. Begemann, T. Zuberbier, T. Werfel: The human mast cell line HMC-1 binds and responds to C3a but not C3a (desArg). Scand. J. Immunol. 47, 19-24 (1998).